The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 401-411

  Breitner, John C S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Corticosteroids; Glucocorticoids; Inflammation; Nonsteroidal antiinflammatory drugs; Prevention; Treatment

Indexed keywords

GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; BRAIN METABOLISM; CELL DEATH; HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; GLUCOCORTICOIDS; HUMANS; STEROIDS;

EID: 0030000385     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.401     Document Type: Review

References (81)

1. Wagstaff AJ, McTavish D. 1994. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 4:510-40
2. Cordell B. 1994. B-amyloid formation as a potential therapeutic target for Alzheimer's disease. Annu. Rev. Pharmacol. Toxicol. 34:69-89
3. Strittmatter WJ, Weisgraber KH, Goedert M, et al. 1994. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp. Neurol. 125:163-71
4. Breitner JCS. 1991. Clinical genetics and genetic counseling in Alzheimer's disease. Ann. Int. Med. 115:601-6
5. Roses AD. 1994. The Alzheimer diseases. In Current Neurology, ed. SH Appel, 14: 111-41. Chicago: Mosby Yearb.
6. Henderson AS. 1990. Epidemiology of dementing disorders. In Alzheimer's Disease, ed. RJ Wurtman, JH Browdon, S Corkin, et al, pp. 15-25. New York: Raven
7. Breteler MMB, Claus JJ, van Duijn CM, et al. 1992. Epidemiology of Alzheimer's disease. Epidemiol. Rev. 14:59-82
8. Fratiglioni L. 1993. Epidemiology of Alzheimer's disease. Issues of etiology and validity. Acta Neurol. Scand. 87 (Suppl.145):1-70
9. Graves AB, White E, Koepsell TD, et al. 1990. The association between head trauma and Alzheimer's disease. Am. J.Epidemiol. 131:491-501
10. Mortimer JA, van Duijn CM, Chandra V, et al. 1991. Head trauma as a risk factor for Alzheimer's disease: a collaborative reanalysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):S28-S35
11. van Duijn CM, Tanja TA, Haaxma R, et al. 1992. Head trauma and the risk of Alzheimer's disease. Am. J. Epidemiol. 135:775-82
12. Mayeux R, Ottman R, Tang M-X, et al. 1993. Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann. Neurol. 33:494-501
13. Mayeux R, Ottman R, Maestre G, et al. 1995. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 45:555-57
14. Heyman A, Wilkinson WE, Stafford JA, et al. 1984. Alzheimer's disease: a study of epidemiological aspects. Ann. Neurol. 15: 335-41
15. Breteler MMB, van Duijn CM, Chandra V, et al. 1991. Medical history and the risk of Alzheimer's disease: a collaborative reanalysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):S36-S42
16. Jorm AF, van Duijn CM, Chandra V, et al. 1991. Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int. J. Epidemiol. 20(Suppl. 2):S43-S47
17. Plassman BL, Steffens DC, Helms MJ, et al. 1995. Depression and APOE genotype as risk factors for Alzheimer's disease. J. Int. Neuropsychol. Soc. In press
18. Mortimer JA. 1995. Presented at the Annu. Meet. Am. Psychopathol. Assoc., New York
19. Zhang MY, Katzman R, Salmon D, et al. 1990. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann. Neurol. 27:428-37
20. Hebert LE, Scherr PA, Beckett LA, et al. 1992. Relation of smoking and alcohol consumption to incident Alzheimer's disease. Am. J. Epidemiol. 135:347-55
21. McDowell I, Hill G, Lindsay J, et al. 1994. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 44:2073-80
22. Stern Y, Gurland B, Tatemichi TK, et al. 1994. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271:1004-10
23. Schofield PW, Mosesson RE, Stern Y, Mayeux R. 1995. The age at onset of Alzheimer's disease and an intracranial area measurement. Arch. Neurol. 52:95-98
24. Katzman R, Terry R, DeTeresa R, et al. 1988. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann. Neurol. 23: 138-44
25. Satz P. 1993. Brain reserve capacity on symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology 7:273-95
26. Jenkinson ML, Bliss MR, Brain AT, Scott DL. 1989. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol. 28:86-88
27. Broe GA, Henderson AS, Creasey H, et al. 1990. A case-control study of Alzheimer's disease in Australia. Neurology 40: 1698-707
28. Li G, Shen YC, Li YT, et al. 1992. A case-control study of Alzheimer's disease in China. Neurology 42:1481-88
29. Myllykangas-Luosujarvi R, Isomaki H. 1994. Alzheimer's disease and rheumatoid arthritis. Br. J. Rheumatol. 33:501-2
30. McGeer PL, McGeer E, Rogers J, Sibley J. 1990. Anti-inflammatory drugs and Alzheimer disease. Lancet 335:1037
31. Lucca U, Tettamanti M, Forloni G, Spagnoli A. 1994. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol. Psychiatry 36:854-56
32. Holstein J, Chatellier G, Piette F, Moulias R. 1994. Prevalence of associated diseases in different types of dementia among elderly institutionalized patients; analysis of 3447 records. J. Am. Geriatr. Soc. 42: 972-77
33. McGeer PL, Harada N, Kimura H, et al. 1992. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia 3: 146-49
34. Chui DH, Tabira T, Izumi S, et al. 1994. Decreased beta-amyloid and increased abnormal Tau depostion in the brain of aged patients with leprosy. Am. J. Pathol. 145: 771-75
35. Rich JB, Rasmusson DX, Folstein MF, et al. 1995. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55
36. Aisen PS. 1995. Anti-inflammatory therapy for Alzheimer's disease. Dementia 9: 173-82
37. Breitner JCS, Welsh KA, Helms MJ, et al. 1995. Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16:523-30
38. Kukull WA, Larson EB, Stergachis A, et al. 1994. Non-steroidal anti-inflammatory drug use and risk of Alzheimer's disease. Neurology 44(Suppl. 2):A237 (Abstr.)
39. Graves AB, White E, Koepsell TD, et al. 1990. A case-control study of Alzheimer's disease. Ann. Neurol. 28:766-74
40. Henderson AS, Jorm AF, Korten AE, et al. 1992. Environmental risk factors for Alzheimer's disease: their relationship to age of onset and to familial or sporadic types. Psychol. Med. 22:429-36
41. Andersen K, Launer LJ, Ott A, et al. 1995. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 45: 1441-45
42. Breitner JCS. 1994. New epidemiologic strategies in Alzheimer's disease may provide clues to prevention and cause. Neurobiol. Aging 150:S175-77
43. Breitner JCS, Gau BA, Welsh KA, et al. 1994. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44:227-32
44. Aisen PS, Davis KL. 1994. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatry 151: 1105-13
45. McGeer PL, Rogers J, McGeer EG. 1994. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis. Assoc. Disord. 8:149-58
46. McGeer PL, McGeer EG. 1995. Chronic inflammatory mechanisms of the brain: implications for the treatment of Alzheimer disease. Dementia 9:111-23
47. Griffin WST, Stanley LC, Ling C, et al. 1989. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. USA 86:7611-15
48. Bauer J, Strauss S, Schreiter-Gasser U, et al. 1991. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett. 285:111-14
49. Bauer J, Ganter U, Strauss S, et al. 1992. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143:650-57
50. Fillit H, Ding W, Buee L, et al. 1991. Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci. Lett. 129:318-20
51. Abraham CR, Selkoe DJ, Potter H. 1988. Immunohistochemical identification of the serine protease inhibitor alpha-1 antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501
52. Rozemuller JM, Stam FC, Eikelenboom P. 1990. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci. Lett. 109: 75-78
53. Lieberburg I, Spinner N, Snyder S, et al. 1989. Cloning of a cDNA encoding the rat high molecular weight neurofilament peptide (NF-H): develomental and tissue expression in the rat, and mapping of its human homologue to chromosomes 1 and 22. Proc. Natl. Acad. Sci. USA 86:2463-67
54. Goldgaber D, Harris HW, Hla T, et al. 1989. Interleukin-1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA 86:7606-10
55. Altstiet L, Sperber K. 1991. Cytokines in Alzheimer's disease. Biol. Psychiatry 15: 481-95
56. Roberts GW, Gentleman SM, Lynch A, et al. 1994. B-amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J. Neurol. 57:419-25
57. McGeer PL, Kawamata T, Walker DG, et al. 1993. Microglia in degenerative neurological disease. Glia 7:84-92
58. Haga S, Ikeda K, Sato M, Ishii T. 1993. Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 601:88-94
59. McGeer PL, Akiyama H, Itagaki S, McGeer EG. 1989. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-27
60. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. 1989. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci. Lett. 101:288-92
61. Colton AC, Gilbert DL. 1987. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 223: 284-88
62. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. 1993. Cytotoxicity of microglia. Glia 7:111-18
63. Corradin SB, Mauel J, Donini SD, et al. 1993. Inducible nitric oxide synthase activity of cloned murine microglial cells. Glia 7:255-62
64. Giulian D. 1993. Reactive glia as rivals in regulating neuronal survival. Glia 7: 102-10
65. Walker DG, Kim SU, McGeer PL. 1995. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J. Neurosci. Res. 40:478-93
66. Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. 1989. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B 56:259-62
67. Lue LF, Rogers J. 1992. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308-13
68. Vane J. 1994. Towards a better aspirin. Nature 367:215-16
69. Vane J, Botting R. 1987. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1:89-96
70. Smith WL, Borgeat P. 1991. In Biochemistry of Lipids, Lipoproteins and Membranes, ed. DE Vance, J Vance, pp. 297-325. New York: Elsevier
71. Smith WL, Marnett LJ. 1991. Prostaglandin endoperoxide synthase: structure and catalysis. FASEB J. 1083:1-17
72. O'Banion MK, Winn VD, Young DA. 1992. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA 89:4888-92
73. Lerea LS, McNamara JO. 1993. Ionotropic glutamate receptor subtypes activate c-fos transcription by distinct calcium-requiring intracellular signaling pathways. Neuron 10:31-41
74. Madison DV, Malenka RC, Nicoll RA. 1991. Mechanisms underlying long-term potentiation of synaptic transmission. Annu. Rev. Neurosci. 14:379-97
75. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-34
76. Smeyne RJ, Vendrell M, Hayward M, et al. 1993. Continuous c-fos expression precedes programmed cell death in vivo. Nature 363:166-69
77. Einstein G, Bautista P, Patel V, et al. 1995. Distribution of apoE-immunoreactive neurons in control and AD brains. Soc. Neurosci. Abstr. 21:1008
78. Koh JY, Yang LL, Cotman CW. 1990. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:315-20
79. Sunami A, Tasaka K. 1991. Two aspects of the excitatory influence of histamine on hippocampal neurons in guinea pigs. Methods Find. Exp. Clin. Pharmacol. 13:85-91
80. Soll AH, Weinstein WM, Kurata J, McCarthy D. 1991. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann. Intern. Med. 114:307-19
81. Rogers J, Kirby LC, Hempelman SR, et al. 1993. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-11